Pharmacokinetics of the First-Line Antituberculosis Drugs in Ghanaian Children with Tuberculosis with or without HIV Coinfection.
Identifieur interne : 000594 ( PubMed/Corpus ); précédent : 000593; suivant : 000595Pharmacokinetics of the First-Line Antituberculosis Drugs in Ghanaian Children with Tuberculosis with or without HIV Coinfection.
Auteurs : Sampson Antwi ; Hongmei Yang ; Anthony Enimil ; Anima M. Sarfo ; Fizza S. Gillani ; Daniel Ansong ; Albert Dompreh ; Antoinette Orstin ; Theresa Opoku ; Dennis Bosomtwe ; Lubbe Wiesner ; Jennifer Norman ; Charles A. Peloquin ; Awewura KwaraSource :
- Antimicrobial agents and chemotherapy [ 1098-6596 ] ; 2017.
Abstract
Although human immunodeficiency virus (HIV) coinfection is the most important risk factor for a poor antituberculosis (anti-TB) treatment response, its effect on the pharmacokinetics of the first-line drugs in children is understudied. This study examined the pharmacokinetics of the four first-line anti-TB drugs in children with TB with and without HIV coinfection. Ghanaian children with TB on isoniazid, rifampin, pyrazinamide, and ethambutol for at least 4 weeks had blood samples collected predose and at 1, 2, 4, and 8 hours postdose. Drug concentrations were determined by validated liquid chromatography-mass spectrometry methods and pharmacokinetic parameters calculated using noncompartmental analysis. The area under the concentration-time curve from 0 to 8 h (AUC0-8), maximum concentration (Cmax), and apparent oral clearance divided by bioavailability (CL/F) for each drug were compared between children with and without HIV coinfection. Of 113 participants, 59 (52.2%) had HIV coinfection. The baseline characteristics were similar except that the coinfected patients were more likely to have lower weight-for-age and height-for-age Z scores (P < 0.05). Rifampin, pyrazinamide, and ethambutol median body weight-normalized CL/F values were significantly higher, whereas the plasma AUC0-8 values were lower, in the coinfected children than in those with TB alone. In the multivariate analysis, drug dose and HIV coinfection jointly influenced the apparent oral clearance and AUC0-8 for rifampin, pyrazinamide, and ethambutol. Isoniazid pharmacokinetics were not different by HIV coinfection status. HIV coinfection was associated with lower plasma exposure of three of the four first-line anti-TB drugs in children. Whether TB/HIV-coinfected children need higher dosages of rifampin, pyrazinamide, and ethambutol requires further investigation. (This study has been registered at ClinicalTrials.gov under identifier NCT01687504.).
DOI: 10.1128/AAC.01701-16
PubMed: 27855070
Links to Exploration step
pubmed:27855070Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Pharmacokinetics of the First-Line Antituberculosis Drugs in Ghanaian Children with Tuberculosis with or without HIV Coinfection.</title><author><name sortKey="Antwi, Sampson" sort="Antwi, Sampson" uniqKey="Antwi S" first="Sampson" last="Antwi">Sampson Antwi</name><affiliation><nlm:affiliation>Directorate of Child Health, Komfo Anokye Teaching Hospital, Kumasi, Ghana.</nlm:affiliation></affiliation></author><author><name sortKey="Yang, Hongmei" sort="Yang, Hongmei" uniqKey="Yang H" first="Hongmei" last="Yang">Hongmei Yang</name><affiliation><nlm:affiliation>Department of Biostatistics and Computational Biology, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Enimil, Anthony" sort="Enimil, Anthony" uniqKey="Enimil A" first="Anthony" last="Enimil">Anthony Enimil</name><affiliation><nlm:affiliation>Directorate of Child Health, Komfo Anokye Teaching Hospital, Kumasi, Ghana.</nlm:affiliation></affiliation></author><author><name sortKey="Sarfo, Anima M" sort="Sarfo, Anima M" uniqKey="Sarfo A" first="Anima M" last="Sarfo">Anima M. Sarfo</name><affiliation><nlm:affiliation>Directorate of Child Health, Komfo Anokye Teaching Hospital, Kumasi, Ghana.</nlm:affiliation></affiliation></author><author><name sortKey="Gillani, Fizza S" sort="Gillani, Fizza S" uniqKey="Gillani F" first="Fizza S" last="Gillani">Fizza S. Gillani</name><affiliation><nlm:affiliation>Department of Medicine, The Miriam Hospital, Providence, Rhode Island, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Ansong, Daniel" sort="Ansong, Daniel" uniqKey="Ansong D" first="Daniel" last="Ansong">Daniel Ansong</name><affiliation><nlm:affiliation>Directorate of Child Health, Komfo Anokye Teaching Hospital, Kumasi, Ghana.</nlm:affiliation></affiliation></author><author><name sortKey="Dompreh, Albert" sort="Dompreh, Albert" uniqKey="Dompreh A" first="Albert" last="Dompreh">Albert Dompreh</name><affiliation><nlm:affiliation>Directorate of Child Health, Komfo Anokye Teaching Hospital, Kumasi, Ghana.</nlm:affiliation></affiliation></author><author><name sortKey="Orstin, Antoinette" sort="Orstin, Antoinette" uniqKey="Orstin A" first="Antoinette" last="Orstin">Antoinette Orstin</name><affiliation><nlm:affiliation>Directorate of Child Health, Komfo Anokye Teaching Hospital, Kumasi, Ghana.</nlm:affiliation></affiliation></author><author><name sortKey="Opoku, Theresa" sort="Opoku, Theresa" uniqKey="Opoku T" first="Theresa" last="Opoku">Theresa Opoku</name><affiliation><nlm:affiliation>Directorate of Child Health, Komfo Anokye Teaching Hospital, Kumasi, Ghana.</nlm:affiliation></affiliation></author><author><name sortKey="Bosomtwe, Dennis" sort="Bosomtwe, Dennis" uniqKey="Bosomtwe D" first="Dennis" last="Bosomtwe">Dennis Bosomtwe</name><affiliation><nlm:affiliation>Directorate of Child Health, Komfo Anokye Teaching Hospital, Kumasi, Ghana.</nlm:affiliation></affiliation></author><author><name sortKey="Wiesner, Lubbe" sort="Wiesner, Lubbe" uniqKey="Wiesner L" first="Lubbe" last="Wiesner">Lubbe Wiesner</name><affiliation><nlm:affiliation>Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa.</nlm:affiliation></affiliation></author><author><name sortKey="Norman, Jennifer" sort="Norman, Jennifer" uniqKey="Norman J" first="Jennifer" last="Norman">Jennifer Norman</name><affiliation><nlm:affiliation>Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa.</nlm:affiliation></affiliation></author><author><name sortKey="Peloquin, Charles A" sort="Peloquin, Charles A" uniqKey="Peloquin C" first="Charles A" last="Peloquin">Charles A. Peloquin</name><affiliation><nlm:affiliation>College of Pharmacy and Emerging Pathogens Institute, University of Florida, Gainesville, Florida, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Kwara, Awewura" sort="Kwara, Awewura" uniqKey="Kwara A" first="Awewura" last="Kwara">Awewura Kwara</name><affiliation><nlm:affiliation>Department of Medicine, The Miriam Hospital, Providence, Rhode Island, USA awewura.kwara@medicine.ufl.edu.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:27855070</idno><idno type="pmid">27855070</idno><idno type="doi">10.1128/AAC.01701-16</idno><idno type="wicri:Area/PubMed/Corpus">000594</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000594</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Pharmacokinetics of the First-Line Antituberculosis Drugs in Ghanaian Children with Tuberculosis with or without HIV Coinfection.</title><author><name sortKey="Antwi, Sampson" sort="Antwi, Sampson" uniqKey="Antwi S" first="Sampson" last="Antwi">Sampson Antwi</name><affiliation><nlm:affiliation>Directorate of Child Health, Komfo Anokye Teaching Hospital, Kumasi, Ghana.</nlm:affiliation></affiliation></author><author><name sortKey="Yang, Hongmei" sort="Yang, Hongmei" uniqKey="Yang H" first="Hongmei" last="Yang">Hongmei Yang</name><affiliation><nlm:affiliation>Department of Biostatistics and Computational Biology, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Enimil, Anthony" sort="Enimil, Anthony" uniqKey="Enimil A" first="Anthony" last="Enimil">Anthony Enimil</name><affiliation><nlm:affiliation>Directorate of Child Health, Komfo Anokye Teaching Hospital, Kumasi, Ghana.</nlm:affiliation></affiliation></author><author><name sortKey="Sarfo, Anima M" sort="Sarfo, Anima M" uniqKey="Sarfo A" first="Anima M" last="Sarfo">Anima M. Sarfo</name><affiliation><nlm:affiliation>Directorate of Child Health, Komfo Anokye Teaching Hospital, Kumasi, Ghana.</nlm:affiliation></affiliation></author><author><name sortKey="Gillani, Fizza S" sort="Gillani, Fizza S" uniqKey="Gillani F" first="Fizza S" last="Gillani">Fizza S. Gillani</name><affiliation><nlm:affiliation>Department of Medicine, The Miriam Hospital, Providence, Rhode Island, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Ansong, Daniel" sort="Ansong, Daniel" uniqKey="Ansong D" first="Daniel" last="Ansong">Daniel Ansong</name><affiliation><nlm:affiliation>Directorate of Child Health, Komfo Anokye Teaching Hospital, Kumasi, Ghana.</nlm:affiliation></affiliation></author><author><name sortKey="Dompreh, Albert" sort="Dompreh, Albert" uniqKey="Dompreh A" first="Albert" last="Dompreh">Albert Dompreh</name><affiliation><nlm:affiliation>Directorate of Child Health, Komfo Anokye Teaching Hospital, Kumasi, Ghana.</nlm:affiliation></affiliation></author><author><name sortKey="Orstin, Antoinette" sort="Orstin, Antoinette" uniqKey="Orstin A" first="Antoinette" last="Orstin">Antoinette Orstin</name><affiliation><nlm:affiliation>Directorate of Child Health, Komfo Anokye Teaching Hospital, Kumasi, Ghana.</nlm:affiliation></affiliation></author><author><name sortKey="Opoku, Theresa" sort="Opoku, Theresa" uniqKey="Opoku T" first="Theresa" last="Opoku">Theresa Opoku</name><affiliation><nlm:affiliation>Directorate of Child Health, Komfo Anokye Teaching Hospital, Kumasi, Ghana.</nlm:affiliation></affiliation></author><author><name sortKey="Bosomtwe, Dennis" sort="Bosomtwe, Dennis" uniqKey="Bosomtwe D" first="Dennis" last="Bosomtwe">Dennis Bosomtwe</name><affiliation><nlm:affiliation>Directorate of Child Health, Komfo Anokye Teaching Hospital, Kumasi, Ghana.</nlm:affiliation></affiliation></author><author><name sortKey="Wiesner, Lubbe" sort="Wiesner, Lubbe" uniqKey="Wiesner L" first="Lubbe" last="Wiesner">Lubbe Wiesner</name><affiliation><nlm:affiliation>Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa.</nlm:affiliation></affiliation></author><author><name sortKey="Norman, Jennifer" sort="Norman, Jennifer" uniqKey="Norman J" first="Jennifer" last="Norman">Jennifer Norman</name><affiliation><nlm:affiliation>Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa.</nlm:affiliation></affiliation></author><author><name sortKey="Peloquin, Charles A" sort="Peloquin, Charles A" uniqKey="Peloquin C" first="Charles A" last="Peloquin">Charles A. Peloquin</name><affiliation><nlm:affiliation>College of Pharmacy and Emerging Pathogens Institute, University of Florida, Gainesville, Florida, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Kwara, Awewura" sort="Kwara, Awewura" uniqKey="Kwara A" first="Awewura" last="Kwara">Awewura Kwara</name><affiliation><nlm:affiliation>Department of Medicine, The Miriam Hospital, Providence, Rhode Island, USA awewura.kwara@medicine.ufl.edu.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Antimicrobial agents and chemotherapy</title><idno type="eISSN">1098-6596</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Although human immunodeficiency virus (HIV) coinfection is the most important risk factor for a poor antituberculosis (anti-TB) treatment response, its effect on the pharmacokinetics of the first-line drugs in children is understudied. This study examined the pharmacokinetics of the four first-line anti-TB drugs in children with TB with and without HIV coinfection. Ghanaian children with TB on isoniazid, rifampin, pyrazinamide, and ethambutol for at least 4 weeks had blood samples collected predose and at 1, 2, 4, and 8 hours postdose. Drug concentrations were determined by validated liquid chromatography-mass spectrometry methods and pharmacokinetic parameters calculated using noncompartmental analysis. The area under the concentration-time curve from 0 to 8 h (AUC0-8), maximum concentration (Cmax), and apparent oral clearance divided by bioavailability (CL/F) for each drug were compared between children with and without HIV coinfection. Of 113 participants, 59 (52.2%) had HIV coinfection. The baseline characteristics were similar except that the coinfected patients were more likely to have lower weight-for-age and height-for-age Z scores (P < 0.05). Rifampin, pyrazinamide, and ethambutol median body weight-normalized CL/F values were significantly higher, whereas the plasma AUC0-8 values were lower, in the coinfected children than in those with TB alone. In the multivariate analysis, drug dose and HIV coinfection jointly influenced the apparent oral clearance and AUC0-8 for rifampin, pyrazinamide, and ethambutol. Isoniazid pharmacokinetics were not different by HIV coinfection status. HIV coinfection was associated with lower plasma exposure of three of the four first-line anti-TB drugs in children. Whether TB/HIV-coinfected children need higher dosages of rifampin, pyrazinamide, and ethambutol requires further investigation. (This study has been registered at ClinicalTrials.gov under identifier NCT01687504.).</div></front></TEI><pubmed><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">27855070</PMID><DateCreated><Year>2016</Year><Month>11</Month><Day>17</Day></DateCreated><DateRevised><Year>2017</Year><Month>07</Month><Day>24</Day></DateRevised><Article PubModel="Electronic-Print"><Journal><ISSN IssnType="Electronic">1098-6596</ISSN><JournalIssue CitedMedium="Internet"><Volume>61</Volume><Issue>2</Issue><PubDate><Year>2017</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Antimicrobial agents and chemotherapy</Title><ISOAbbreviation>Antimicrob. Agents Chemother.</ISOAbbreviation></Journal><ArticleTitle>Pharmacokinetics of the First-Line Antituberculosis Drugs in Ghanaian Children with Tuberculosis with or without HIV Coinfection.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">e01701-16</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1128/AAC.01701-16</ELocationID><Abstract><AbstractText>Although human immunodeficiency virus (HIV) coinfection is the most important risk factor for a poor antituberculosis (anti-TB) treatment response, its effect on the pharmacokinetics of the first-line drugs in children is understudied. This study examined the pharmacokinetics of the four first-line anti-TB drugs in children with TB with and without HIV coinfection. Ghanaian children with TB on isoniazid, rifampin, pyrazinamide, and ethambutol for at least 4 weeks had blood samples collected predose and at 1, 2, 4, and 8 hours postdose. Drug concentrations were determined by validated liquid chromatography-mass spectrometry methods and pharmacokinetic parameters calculated using noncompartmental analysis. The area under the concentration-time curve from 0 to 8 h (AUC0-8), maximum concentration (Cmax), and apparent oral clearance divided by bioavailability (CL/F) for each drug were compared between children with and without HIV coinfection. Of 113 participants, 59 (52.2%) had HIV coinfection. The baseline characteristics were similar except that the coinfected patients were more likely to have lower weight-for-age and height-for-age Z scores (P < 0.05). Rifampin, pyrazinamide, and ethambutol median body weight-normalized CL/F values were significantly higher, whereas the plasma AUC0-8 values were lower, in the coinfected children than in those with TB alone. In the multivariate analysis, drug dose and HIV coinfection jointly influenced the apparent oral clearance and AUC0-8 for rifampin, pyrazinamide, and ethambutol. Isoniazid pharmacokinetics were not different by HIV coinfection status. HIV coinfection was associated with lower plasma exposure of three of the four first-line anti-TB drugs in children. Whether TB/HIV-coinfected children need higher dosages of rifampin, pyrazinamide, and ethambutol requires further investigation. (This study has been registered at ClinicalTrials.gov under identifier NCT01687504.).</AbstractText><CopyrightInformation>Copyright © 2017 American Society for Microbiology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Antwi</LastName><ForeName>Sampson</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Directorate of Child Health, Komfo Anokye Teaching Hospital, Kumasi, Ghana.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Child Health, School of Medical Sciences, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Hongmei</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Biostatistics and Computational Biology, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Enimil</LastName><ForeName>Anthony</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Directorate of Child Health, Komfo Anokye Teaching Hospital, Kumasi, Ghana.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Child Health, School of Medical Sciences, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sarfo</LastName><ForeName>Anima M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Directorate of Child Health, Komfo Anokye Teaching Hospital, Kumasi, Ghana.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gillani</LastName><ForeName>Fizza S</ForeName><Initials>FS</Initials><AffiliationInfo><Affiliation>Department of Medicine, The Miriam Hospital, Providence, Rhode Island, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Warren Alpert Medical School of Brown University, Providence, Rhode Island, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ansong</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Directorate of Child Health, Komfo Anokye Teaching Hospital, Kumasi, Ghana.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Child Health, School of Medical Sciences, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dompreh</LastName><ForeName>Albert</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Directorate of Child Health, Komfo Anokye Teaching Hospital, Kumasi, Ghana.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Orstin</LastName><ForeName>Antoinette</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Directorate of Child Health, Komfo Anokye Teaching Hospital, Kumasi, Ghana.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Opoku</LastName><ForeName>Theresa</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Directorate of Child Health, Komfo Anokye Teaching Hospital, Kumasi, Ghana.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bosomtwe</LastName><ForeName>Dennis</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Directorate of Child Health, Komfo Anokye Teaching Hospital, Kumasi, Ghana.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wiesner</LastName><ForeName>Lubbe</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Norman</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peloquin</LastName><ForeName>Charles A</ForeName><Initials>CA</Initials><AffiliationInfo><Affiliation>College of Pharmacy and Emerging Pathogens Institute, University of Florida, Gainesville, Florida, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kwara</LastName><ForeName>Awewura</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Medicine, The Miriam Hospital, Providence, Rhode Island, USA awewura.kwara@medicine.ufl.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Warren Alpert Medical School of Brown University, Providence, Rhode Island, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT01687504</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>R01 HD071779</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UM1 AI068634</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UM1 AI106701</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AI078498</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AI042853</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UM1 AI068636</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>01</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Antimicrob Agents Chemother</MedlineTA><NlmUniqueID>0315061</NlmUniqueID><ISSNLinking>0066-4804</ISSNLinking></MedlineJournalInfo><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>Clin Infect Dis. 2009 Jun 15;48(12):1685-94</RefSource><PMID Version="1">19432554</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Int J Tuberc Lung Dis. 2015 Nov;19(11):1305-11</RefSource><PMID Version="1">26467582</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Infect Dis. 2005 Jul 1;41(1):83-91</RefSource><PMID Version="1">15937767</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS. 1997 Jul 15;11(9):1151-8</RefSource><PMID Version="1">9233463</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>BMC Infect Dis. 2007 Nov 29;7:140</RefSource><PMID Version="1">18047651</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Int J Tuberc Lung Dis. 2002 Aug;6(8):672-8</RefSource><PMID Version="1">12150478</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Appl Stat. 2011 Jan 1;5(1):232-253</RefSource><PMID Version="1">22081779</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Antimicrob Agents Chemother. 2006 Feb;50(2):407-13</RefSource><PMID Version="1">16436690</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS. 2010 Jun 1;24(9):1341-9</RefSource><PMID Version="1">20559039</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Chest. 2001 Nov;120(5):1520-4</RefSource><PMID Version="1">11713129</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Infect Dis. 2007 Aug 15;196 Suppl 1:S76-85</RefSource><PMID Version="1">17624829</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Infect Dis. 2000 Jul;31(1):170-6</RefSource><PMID Version="1">10913417</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Intern Med. 1997 Aug 15;127(4):289-93</RefSource><PMID Version="1">9265429</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Pulm Pharmacol Ther. 2012 Feb;25(1):83-6</RefSource><PMID Version="1">22179055</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Pharmacother. 1996 Sep;30(9):919-25</RefSource><PMID Version="1">8876848</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Pediatr Infect Dis J. 2016 May;35(5):530-4</RefSource><PMID Version="1">26825153</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Pediatr Infect Dis J. 2005 Aug;24(8):685-91</RefSource><PMID Version="1">16094221</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Infect Dis. 1997 Jul;25(1):104-11</RefSource><PMID Version="1">9243044</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Antimicrob Agents Chemother. 2015 Feb;59(2):1162-7</RefSource><PMID Version="1">25487804</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>World Health Organ Tech Rep Ser. 1995;854:1-452</RefSource><PMID Version="1">8594834</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>BMC Med. 2009 Apr 22;7:19</RefSource><PMID Version="1">19386087</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Paediatr Respir Rev. 2011 Mar;12(1):22-6</RefSource><PMID Version="1">21172671</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Antimicrob Agents Chemother. 2016 Mar 25;60(4):2171-9</RefSource><PMID Version="1">26810651</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Antimicrob Agents Chemother. 2011 Dec;55(12):5560-7</RefSource><PMID Version="1">21968358</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Pediatr Infect Dis J. 2005 Dec;24(12):1077-82</RefSource><PMID Version="1">16371869</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Int J Tuberc Lung Dis. 2016 May;20(5):666-72</RefSource><PMID Version="1">27084822</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Int J Tuberc Lung Dis. 2013 Feb;17(2):221-4</RefSource><PMID Version="1">23317957</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Arch Dis Child. 2005 Nov;90(11):1171-4</RefSource><PMID Version="1">15964862</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Pediatric Infect Dis Soc. 2016 Dec;5(4):356-365</RefSource><PMID Version="1">26407268</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Infect Dis. 2005 Dec 1;41(11):1638-47</RefSource><PMID Version="1">16267738</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Am J Respir Crit Care Med. 2006 Nov 15;174(10):1153-8</RefSource><PMID Version="1">16908866</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Infect Dis. 2005 May 15;40(10):1481-91</RefSource><PMID Version="1">15844071</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Pediatr Infect Dis J. 2002 Nov;21(11):1053-61</RefSource><PMID Version="1">12442029</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Antimicrob Agents Chemother. 2015 Oct;59(10):6175-80</RefSource><PMID Version="1">26248378</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Infect Dis. 2005 Aug 15;41(4):461-9</RefSource><PMID Version="1">16028152</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 1995 Feb 2;332(5):336-7</RefSource><PMID Version="1">7816080</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Int J Tuberc Lung Dis. 1998 Aug;2(8):670-5</RefSource><PMID Version="1">9712282</PMID></CommentsCorrections></CommentsCorrectionsList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">children</Keyword><Keyword MajorTopicYN="N">first-line anti-TB drugs</Keyword><Keyword MajorTopicYN="N">human immunodeficiency virus</Keyword><Keyword MajorTopicYN="N">pharmacokinetics</Keyword><Keyword MajorTopicYN="N">tuberculosis</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>08</Month><Day>04</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>11</Month><Day>05</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>11</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>11</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>11</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27855070</ArticleId><ArticleId IdType="pii">AAC.01701-16</ArticleId><ArticleId IdType="doi">10.1128/AAC.01701-16</ArticleId><ArticleId IdType="pmc">PMC5278726</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/SidaGhanaV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000594 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000594 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= SidaGhanaV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:27855070
|texte= Pharmacokinetics of the First-Line Antituberculosis Drugs in Ghanaian Children with Tuberculosis with or without HIV Coinfection.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:27855070" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a SidaGhanaV1
| This area was generated with Dilib version V0.6.31. |  |